Venöz tromboembolizm ve kanser

Venöz tromboemboli (VTE) kanser hastalarında mortalite ve morbidite üzerinde önemli etkileri olan komplikasyonlardan birisidir. VTEgelişen kanser hastalarında erken mortalite geliş me oran ı daha yüksektir. Bu komplikasyon kanserin hücre tipi ve evresi, tedavi esna-sında uygulanan kanser cerrahisi, kateter uygulaması, kemoterapötik ajanlarla ilişkilidir. Kanser hastaların ın tedavi ve takiplerinde VTEprofilaksisi ve/veya tedavisi mortalite ve morbidite oranlarında azalmayı sa ğlayacaktır. VTE profilaksisi ve tedavisi, hastaların gerekkanser tipi, gerekse uygulanacak tedavi yakla şımlarına göre farklılıklar arz etmektedir. Bu derlemede uluslararas ı uzla şı raporları dik-kate alınarak patogenez, risk faktörleri ve tedavi yakla şımların ın anlatılması hedeflenmiştir.

Venous thromboembolism and cancer

Venous thromboembolism (VTE) is one of the complications which have significant influence on mortality in patient with cancer.Early mortality rate is high in cancer patients who have VTE. This complication is related with cell type and stage of the cancer,surgery applied during cancer treatment, applying catheter and the chemotherapeutic agents. VTE prophylaxis and/or treatment intreatment and follow-up of cancer patients will provide a reduction in mortality and morbidity rates. VTE prophylaxis and treatmentposes differences according to both treatment approaches which will be applied and the type of cancer. It has been aimed todescribe pathogenesis, risk factors and treatment approaches taking into account international consensus reports in this review.

PDF

___

1. Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, et al. Rates of initial and recurrent thromboem- bolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999;78(5):285-91.
2. Trousseau A. Phlegmasia alba dolens. Clin Med Hotel-Dieu Paris 1865;3:654-712.
3. Agnelli G, Verso M, Management of venous thromboembo- lism in patients with cancer. J Throm Haemost 2011;9(Suppl 1):316-24.
4. Shinagare AB, Guo M, Hatabu H, Krajewski KM, Andriole K, Van den Abbeele AD, et al. Incidence of pulmonary embolism in oncologic outpatients at a tertiary cancer center. Cancer 2011;117(16):3860-6.
5. Johnson MJ, Sproule MW, Paul J. The prevalence and asso- ciated variables of deep venous thrombosis in patients with advanced cancer. Clin Oncol (R Coll Radiol) 1999;11(2):105-10.
6. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006;166(4):458-64.
7. Jones A, Stockton DL, Simpson AJ, Murchison JT. Idiopathic venous thromboembolic disease is associated with a poor- er prognosis from subsequent malignancy. Br J Cancer 2009;101:840.
8. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombo- sis. JAMA 2005;293(6):715-22.
9. Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboem- bolism in a prospective observational study. Cancer 2005;104(12):2822-9.
10. Perry JR, Julian JA, Laperriere NJ, Geerts W, Agnelli G, Rogers LR, et al. PRODIGE: a randomized placebo-con- trolled trial of dalteparin low molecular weight heparin (LMWH) thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 2010;8(9):1959-65.
11. Srkalovic G, Cameron MG, Rybicki L, Deitcher SR, KAttke- MArchant K, Hussein MA. Monoclonal gammopathy of undetermined significance and multiple myeloma are asso- ciated with an increased incidence of venothromboem- bolic disease. Cancer 2004;101(3):558-66.
12. Otten HM, Mathijssen J, ten Cate H, Soesan M, Inghels M, Richel DJ, et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy, an underesti- mated phenomenon. Arch Intern Med 2004;164:190-4.
13. Cheruku R, Tapazoglou E, Ensley J, Kish JA, Cummings GD, al-Sarraf M. The incidence and significance of thromboem- bolic complications in patients with high-grade gliomas. Cancer 1991;68:2621-4. 14. Clahsen PC, van de Velde CJ, Julien JP, Floiras JL, Mignolet FY. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study. J Clin Oncol 1994;12(6):1266-71.
15. Prandoni P, Piccioli A. Venous thromboembolism and can- cer: A two-way clinical association Frontiers in Bioscience 1997;2:12-21.
16. Rogers JS II, Murgo AJ, Fontana JA, Raich PC. Chemotherapy for breast cancer decreases plasma protein C and protein S. J Clin Oncol 1988;6:276-81.
17. Rella C, Coviello M, Giotta F, Maiello E, Colavito D, Colangelo D, et al. A prothrombotic state in breast cancer patients treated with adjuvant chemotherapy. Breast Cancer Res Treat 1996;40(2):151-9.
18. Levine MN, Gent M, Hirsh J, Arnoid A, Goodyear MD, Hrynuik W, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988;318:404-7.
19. Demirkan B, Ozcan MA, Glu AA, Yüksel F, Undar B, Alakavuklar M. The effect of anthracycline-based (Epirubicin) adjuvant chemotherapy on plasma TAFI and PAI-1 levels in operable breast cancer. Clin Appl Thromb. Hemost 2006;12(1):9-14.
20. Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerham DL, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor positive breast cancer. J Natl. Cancer Inst 1997;89:1673-82.
21. Pritchard KI, Paterson AH, Paul NA, Zee B, Pater J. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adju- vant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol 1996;14(10):2731-7.
22. Kato A, Takano H, Ichikawa A, Koshino M, Igararshi A, Hattori K, et al. Retrospective cohort study of venous thromboembolism (VTE) in 1035 Japanese myeloma patients treated with thalidomide; lower incidence without statistically significant association between specific risk fac- tors and development of VTE and effects of thrombo- prophylaxis with aspirin and warfarin. Thromb Res 2013;131(2):140-4.
23. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, et al. Prevention of thalido- mide and lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22:414-23.
24. El Accaoui RN, Shamseddeen WA, Taher AT. Thalidomide and thrombosis - A meta-analysis. Thromb Haemost 2007;97(6):1031-6.
25. Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A, et al; Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 2008;112(12):4445-51.
26. Alexander M, Teoh KC, Lingaratnam S, Kirsa S, Mellor JD. Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalido- mide or thalidomide at a specialist cancer hospital. Asia Pac J Clin Oncol 2013;9(2):169-75.
27. Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE, et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemothera- py: A large retrospective analysis. J Clin Oncol 2011;29(25):3466-73.
28. Seng S, Liu Z, Chiu SK, Proverbs-Singh T, Sonpavde G, Choueiri TK, et al. Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. J Clin Oncol 2012;30(35):4416-26.
29. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008;300(19):2277-85.
30. Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 2010;49(3):287-9728.
31. Bennett CL, Spiegel DM, Macdougall IC, Norris L, Qureshi ZP, Sartor O, et al. A review of safety, efficacy, and utiliza- tion of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: A report from the southern network on adverse reactions (SONAR). Semin Thromb Hemost 2012;38(8):783-96.
32. Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2012;12:CD003407
33. Truelove E, Fielding AK, Hunt BJ. The coagulopathy and thrombotic risk associated with L-asparaginase treatment in adults with acute lymphoblastic leukaemia. Leukemia 2013;27(3):553-9.
34. Dubashi B, Jain A. L-Asparginase induced cortical venous thrombosis in a patient with acute leukemia. J Pharmacol Pharmacother 2012;3(2):194-5.
35. Guzmán-Uribe P, Rosas-López A, Zepeda-León J, Crespo- Solís E. Incidence of thrombosis in adults with acute leuke- mia: a single center experience in Mexico. Rev Invest Clin 2013;65(2):130-40.
36. Hammond J, Kozma C, Hart JC, Nigam S, Daskiran M, Paris A, et al. Rates of venous thromboembolism among patients with major surgery for cancer. Ann Surg Oncol 2011;18:3240-7.
37. Agnelli G, Bolis G, Capussotti L, Scarpa RM, Tonelli F, Bonizzoni E, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery the @RISTOS project. Ann Surg 2006;243(1):89-95.
38. Christensen TD, Vad H, Pedersen S, Hvas AM, Wotton R, Naidu B, et al. Venous thromboembolism in patients undergoing operations for lung cancer: a systematic review. Ann Thorac Surg 2014;97:394-400.
39. Hennessey P, Semenov YR, Gourin CG. The effect of deep venous thrombosis on short-term outcomes and cost of care after head and neck cancer surgery. Laryngoscope 2012;122(10):2199-204.
40. Lee AY, Levine MN, Butler G, Webb C, Costantini L, Gu C, et al. Incidence, risk factors, and outcomes of catheter- related thrombosis in adult patients with cancer. J Clin Oncol 2006;24:1404-8.
41. Verso M, Agnelli G, Bertoglio S, Di Somma FC, Paoletti F, Ageno W, et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a doubleblind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 2005;23:4057-62.
42. Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003;21(19):3665-75.
43. Gaddh M, Antun A, Yamada K, Gupta P, Tran H, El Rassi F, et al Venous access catheter-related thrombosis in patients with cancer. Leuk Lymphoma 2014;55(3):501-8.
44. Saber W, Moua T, Williams EC, Verso M, Agnelli G, Couban S, et al. Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta- analysis of clinical trials and prospective studies. J Thromb Haemost 2011;9:312-9.
45. Kuter DJ. Thrombotic complications of central venous catheters in cancer patients. Oncologist 2004;9(2):207-16.
46. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous throm- boembolism among hospitalized cancer patients. Cancer 2007;110(10):2339-46.
47. Streiff MB, Bockenstedt PL, Cataland SR, Chesney C, Eby C, Fanikos J, et al Venous thromboembolic disease. J Natl Compr Canc Netw 2011;9:714-77.
48. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, et al. Prevention of thalido- mide-and lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22:414-23.
49. Simanek R, Vormittag R, Ay G, Alguel G, Dunkler D, Schwarzinger I, et al. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). J Thromb Haemost 2010;8(1):114-20.
50. Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R, et al. Prediction of venous thromboembolism in cancer patients. Blood 2010;116(24)5377-82. 51. Miller GJ, Bauer KA, Howarth DJ, Cooper JA, Humphries SE, Rosenberg RD. Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost 2004;2:2107-14.
52. Welsh J, Smith JD, Yates KR, Greenman J, Maravevas A, Madden LA. Tissue factor expression determines tumour cell coagulation kinetics. Int J Lab Hematol, 2012;34(4):396-402.
53. Kasthuri RS, Taubman MB, Mackman N. Role of tissue fac- tor in cancer. J Clin Oncol 2009;27(29):4834-8.
54. Davila M, Amirkhosravi A, Coll E, Desai H, Robles L, Colon J, et al. Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J Thromb Haemost 2008;6:1517-24.
55. Zwicker JI, Liebman HA, Neuberg D, Lacroix R, Bauer KA, Furie BC, et al. Tumor-derived tissue factor-bearing micro- particles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 2009;15:6830-40.
56. Zwicker JI, Liebman HA, Bauer KA, Caughey T, Campigotto F, Rosovsky R, et al. Prediction and prevention of thrombo- embolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a rand- omized-controlled phase II trial (the Microtec study). Br J Haematol 2013;160(4):530-7.
57. Zhang X, Yu H, Lou JR, Zheng J, Zhu H, Popescu NI, et al. MicroRNA-19 (miR-19) regulates tissue factor expression in breast cancer cells. J Biol Chem 2011;286:1429-35.
58. Rautou PE, Mackman N. Microvesicles as risk markers for venous thrombosis. Expert Rev Hematol 2013;6(1):91-101.
59. Molnar S, Guglielmone H, Lavarda M, Rizzi ML, Jarchum G. Procoagulant factors in patients with cancer. Hematology 2007;12(6):555-9.
60. Falanga A, Lacoviello L, Evangelista V, Belotti D, Consonni R, DOrazio A, et al. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retin- oic acid. Blood 1995;86:1072-81.
61. Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, et al; Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-8.
62. Zwicker JI, Furie BC, Furie B. Cancer-associated thrombo- sis. Crit Rev Oncol Hematol 2007;62:126-36.
63. Hoffman R, Haim N, Brenner B. Cancer and thrombosis revisited. Blood Rev 2001;15:61-7.
64. Sood A, Stone RL, Afshar-Kharghan V. Causes and conse- quences of cancer-associated thrombocytosis. Blood 2013;122(21):SCI-33.
65. Riedl J, Pabinger I, Ay C. Platelets in cancer and thrombo- sis.Hamostaseologie 2014;34(1):54-62.
66. Chen M, Geng JG. P-selectin mediates adhesion of leuko- cytes, platelets, and cancer cells in inflammation, thrombo- sis, and cancer growth and metastasis. Arch Immunol Ther Exp (Warsz) 2006;54:75-84.
67. Haddad TC, Greeno EW. Chemotherapy-induced throm- bosis. Thromb Res 2006;118(5):555-68.
68. MismettiP, Laporte S, Darmon JY, Buchmüller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001;88(7):913-30.
69. Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B, et al. International clinical practice guide- lines for the treatment and prophylaxis of venous thrombo- embolism in patients with cancer. J Thromb Haemost 2013;11(1):56-70.
70. Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol 2013;31(17):2189-204.
71. Mandalà M, Falanga A, Roila F; ESMO Guidelines Working Group. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2011;22(Suppl 6):vi85-92.
72. Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, et al. Nadroparin for the prevention of throm- boembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009;10(10):943-9.
73. Haas SK, Freund M, Heigener D, Heilmann L, Kemkes- Matthes B, von Tempelhoff GF, et al. Low-molecular-weight heparin versus placebo for the prevention of venous throm- boembolism in metastatic breast cancer or stage III/IV lung cancer. Clin Appl Thromb Hemost 2012;18(2):159-65.
74. Debourdeau P, Farge D, Beckers M, Baglin C, Bauersachs RM, Brenner B, et al. International clinical practice guide- lines for the treatment and prophylaxis of thrombosis asso- ciated with central venous catheters in patients with can- cer. J Thromb Haemost 2013;11:71-80.
75. Akl EA, Labedi N, Barba M, Terranato I, Sperati F, Muti P, et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2011;15(6):CD006650.
76. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-53.
77. Lee AA, Peterson EA. Treatment of cancer-associated thrombosis Blood 2013;122(14):2310-7.
78. Sun JM, Kim TS, Lee J, Park YH, Ahn JS, Kim H, et al. Unsuspected pulmonary emboli in lung cancer patients: the impact on survival and the significance of anticoagula- tion therapy. Lung Cancer 2010;69:330-6.
79. OConnell C, Razavi P, Ghalichi M, Boyle S, Vasan S, Mark L, et al. Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi-row dedector computed tomography scanning. J Thromb Haemost 2011;9:305-11.
80. Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, et al. American society of clinical oncology guideline: recommendations for venous throm- boembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007;25:5490-5.